RIVENDELL GROUP LLP for GENENTECH
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
MMM - issues and legislation relating generally to the 340B Drug Discount Program; issues relating to Medicare and Medicaid coverage and reimbursement; issues relating to drug pricing; issues related to Part D Medicare Program including coverage gap and other offsets - U.S. Senate and House of Representatives
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Medical/Disease Research/Clinical Labs MED
S. 2582 the Pandemic and All-Hazards Preparedness and Innovation Act of 2018 (PAHPA), H.R. 6378 - to reauthorize certain programs under the Pandemic and All - Hazards Preparedness Reauthorization Act -- U.S. Senate and House of Representatives
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
Health Issues HCR
issues and legislation relating to 340B drug discount program; issues relating to drug pricing; S. 2582 the Pandemic and All-Hazards Preparedness and Innovation Act of 2018 (PAHPA), H.R. 6378 - to reauthorize certain programs under the Pandemic and All - Hazards Preparedness Reauthorization Act -- U.S. Senate and House of Representatives
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.